中医药辅助PD-1单抗治疗非小细胞肺癌的临床辨析

李明花; 柴水珍; 董志毅; 鞠立霞

doi:10.16305/j.1007-1334.2021.2012144

您当前的位置：

首页 >

文章列表页 >

中医药辅助PD-1单抗治疗非小细胞肺癌的临床辨析

临证承启 | 更新时间：2022-08-03

- 中医药辅助PD-1单抗治疗非小细胞肺癌的临床辨析
- Clinical analysis of PD-1 monoclonal antibody supplemented with traditional Chinese medicine in the treatment of non-small cell lung cancer
- 上海中医药杂志 2021年55卷第10期页码：28-30,33
- 作者机构：
  
  1.上海中医药大学附属市中医医院肿瘤科（上海　200071）
  2.同济大学附属上海市肺科医院胸外科（上海　200433）
  3.同济大学附属上海市肺科医院中西医结合科（上海　200433）
- 作者简介：
  
  李明花，女，博士，主治医师，主要从事中西医结合治疗肿瘤的临床与研究工作。
  鞠立霞，副主任医师；E-mail：jvlixia@126.com
- 基金信息：
  
  国家自然科学基金青年基金项目(81207106);上海市科委中医引导项目(17401932400;19401930800);同济大学附属上海市肺科医院学科骨干项目(fkgg1807)
- DOI：10.16305/j.1007-1334.2021.2012144
  中图分类号：
扫描看全文
李明花, 柴水珍, 董志毅, 等. 中医药辅助PD-1单抗治疗非小细胞肺癌的临床辨析[J]. 上海中医药杂志, 2021,55(10):28-30,33.

Minghua LI, Shuizhen CHAI, Zhiyi DONG, et al. Clinical analysis of PD-1 monoclonal antibody supplemented with traditional Chinese medicine in the treatment of non-small cell lung cancer[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(10):28-30,33.
李明花, 柴水珍, 董志毅, 等. 中医药辅助PD-1单抗治疗非小细胞肺癌的临床辨析[J]. 上海中医药杂志, 2021,55(10):28-30,33. DOI： 10.16305/j.1007-1334.2021.2012144.

Minghua LI, Shuizhen CHAI, Zhiyi DONG, et al. Clinical analysis of PD-1 monoclonal antibody supplemented with traditional Chinese medicine in the treatment of non-small cell lung cancer[J]. Shanghai Journal of Traditional Chinese Medicine, 2021,55(10):28-30,33. DOI： 10.16305/j.1007-1334.2021.2012144.

摘要

程序性死亡受体-1（PD-1）单抗的临床应用为非小细胞肺癌的治疗带来了飞跃式的进步，但会造成免疫治疗相关不良反应，且仍有近半数患者难以从中获益。针对非小细胞肺癌PD-1单抗不同治疗阶段的临床表现，将患者分为风热犯肺、脾虚痰湿、气滞血瘀、气阴两虚4种证型，分别以桑菊饮、参苓白术散、血府逐瘀汤、生脉饮合沙参麦冬汤加减对证治疗，可有效改善患者的临床症状，减轻免疫治疗相关不良反应。并附验案1则。

Abstract

The clinical application of programmed death-1(PD-1) has brought remarkable progress in the treatment of non-small cell lung cancer (NSCLC), but it may cause immunotherapy-related adverse reactions and nearly half of the patients still can hardly benefit from it. According to the clinical manifestations at different treatment stages of NSCLC treated with PD-1 monoclonal antibody, four syndromes can be identified among NSCLS patients: wind-heat attacking the lung syndrome, spleen-deficiency and phlegm-dampness syndrome, qi stagnation and blood stasis syndrome, and dual deficiency of qi and yin syndrome. It has been proved that the appropriate application of Sangju Decoction, Shenling Baizhu Powder, Xuefu Zhuyu Decoction, Shengmai Decoction plus Shashen Maidong Decoction to corresponding syndromes can effectively improve the clinical symptoms of patients and reduce adverse reactions related to immunotherapy. One proved case is attached.

关键词

非小细胞肺癌程序性死亡受体-1免疫治疗中医药疗法

Keywords

non-small cell lung cancerprogrammed death-1 (PD-1)immunotherapytraditional Chinese medicine therapy

references

BORGHAEI H, GETTINGER S, VOKES E E, et al. Five-year outcomes from the randomized, phase Ⅲ trials checkmate 017 and 057: Nivolumab versus docetaxel in previously treated non-small-cell lung cancer[J]. J Clin Oncol, 2021, 39(7): 723-733.

XU X L, HUANG Z Y, ZHENG L, et al. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer[J]. Int J Cancer, 2018, 142 (11): 2344-2354.

盖云，史海霞，徐振晔. 程序性死亡受体-1抑制剂致晚期重症肿瘤患者不良事件2例及中医药干预经验报道[J]. 上海中医药杂志，2020, 54(10): 20-23.

叶轩婷，刘苓霜，姜怡，等. 扶正解毒颗粒对非小细胞肺癌术后辅助化疗患者免疫功能和生活质量的影响[J]. 上海中医药杂志，2020, 54(10): 57-61.

苏婉，王中奇，邓海滨，等. 抗瘤减毒方联合参芪扶正注射液改善中晚期非小细胞肺癌患者癌因性疲乏的疗效观察[J]. 上海中医药杂志，2019,53(5): 53-56.

刘追星，杨洋，陈光伟，等. 扶正抗癌方联合化疗对中晚期非小细胞肺癌患者外周血CD4+、CD8+细胞影响的临床研究[J]. 陕西中医药大学学报，2020, 43(5): 76-79.

李明花，董志毅，苏晋梅，等. 益气养阴解毒方延长广泛期小细胞肺癌患者一线化疗疾病无进展生存期的研究[J]. 浙江中医药大学学报，2020, 44(11): 1090-1094.

JIANG Y S, CHEN M, NIE H, et al. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations[J]. Hum Vaccin Immunother, 2019, 15(5): 1111-1122.

GADGEEL S M, STEVENSON J P, LANGER C J, et al. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study[J/OL]. Lung Cancer, 2018,125:273-281[2020-12-05]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886233/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886233/.

LANGER C J, GADGEEL S M, BORGHAEI H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study[J]. Lancet Oncol, 2016, 17(11): 1497-1508.

GANDHI L, RODRIGUEZ-ABREU D, GADGEEL S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell Lung cancer[J]. N Engl J Med, 2018, 378(22): 2078-2092.

PAZ-ARES L, LUFT A, VICENTE D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell Lung cancer[J]. N Engl J Med, 2018, 379(21): 2040-2051.

RIZVI N A, HELLMANN M D, BRAHMER J R, et al. Nivolumab in combination with platinum-based doublet chemotherapy for first-Line treatment of advanced non-small-cell lung cancer[J]. J Clin Oncol, 2016, 34(25): 2969-2979.

HAANEN J B A G, CARBONNEL F, ROBERT C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(Suppl 4): iv119-iv142.

浏览量

489

下载量

CSCD

CNKI被引量

文章被引用时，请邮件提醒。

提交

工具集

关联资源

运用倾向性评分匹配分析益气养精方对Ⅰ～ⅢA期肺腺癌术后患者生存预后的影响

非小细胞肺癌术后中医药分阶段康复治疗策略

中医益气养阴解毒方案联合安罗替尼治疗晚期非小细胞肺癌的疗效与安全性分析

中医辨证治疗联合埃克替尼对EGFR突变老年晚期肺腺癌患者生存期的影响

柴胡疏肝散对功能性消化不良大鼠AMPK/SIRT3信号通路的影响